Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (VHH-Fc-VHH) (HCAB-036)

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (VHH-Fc-VHH, Tetravalent HCAb) is a fusion protein of two diabodies connected together by an Fc region. In a diabody, the two VHHs with short linkers are from anti-CD64 and anti-EGFR antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to the Fc fragment, which results in 2+2 antigen-binding valency and exerts Fc-mediated functions or just extends the half-life. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD64 & EGFR

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

EGFR

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (VHH-Fc-VHH) (HCAB-036). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (VHH-Fc-VHH) (CAT#: HCAB-036)

Specifications

Targets

Customer Reviews and Q&As